Navigation Links
MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
Date:1/12/2009

MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced continued progress with its two Phase 3 clinical programs, Unit Dose Budesonide (UDB) for children with asthma and MAP0004 for the acute treatment of migraine. For UDB, all patients have completed the 12 week treatment period in the initial Phase 3 clinical trial, and for MAP0004, the company currently expects to complete enrollment in its initial Phase 3 clinical trial by the end of January 2009.

"We continue to make good progress with our Phase 3 asthma and migraine programs and look forward to reporting data from both programs during the first half of 2009," said Timothy S. Nelson, President and CEO of MAP Pharmaceuticals. "We believe this clinical progress coupled with our recently announced asthma partnership with AstraZeneca highlights the value of our clinical approach and business strategy."

UDB Phase 3 Program

The initial UDB Phase 3 clinical trial completed enrollment in September 2008, and all patients now have completed the treatment period. This Phase 3 trial is a multi-center, randomized, double-blind, placebo controlled trial in approximately 360 children who suffer from asthma, from 12 months to 8 years of age. Patients received either 0.25mg UDB, 0.135mg UDB or placebo twice a day over a 12 week treatment period. The co-primary efficacy endpoints for the study are the change in nighttime and daytime composite symptom scores (cough, wheeze and breathlessness). Patients enrolled in this trial will continue to be followed in a long-term safety trial.

UDB is being studied as a novel version of nebulized budesonide. Budesonide has been used clinically for more than 20 years. UDB is designed to be nebulized more quickly and at a lower nominal dose than th
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , 27. März 2015 ... Vilcek Prize in Biomedical Science für seine ... wie Proteine zwischen Zellkompartimenten transportiert werden, sowie ... den Zellen zur Reaktion auf Stress nutzen, ... zusammenhängt. Dr. Walter ist Professor für Biochemie ...
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... 12 months ended December 31, 2014.  ... or ($0.05) per share, for the three months ended ...
(Date:3/26/2015)... Bruno, CA (PRWEB) March 26, 2015 ... (CRO), announced today several management and executive appointments ... of Chief Financial Officer (CFO) and member of the ... President of Business Operations, and Sue Dowden will assume ... Taricco, co-founder and current Chief Operations Officer (COO), has ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... VANCOUVER, Oct. 31 /PRNewswire-FirstCall/ - Beanstalk Capital Ltd. ... to the Company,s press,release dated October 16, 2007, ... announced that they had entered into an arm,s ... Agreement"),the Company and iCo would now like to ...
... Corporation plc,(NASDAQ: AMRN ) ("Amarin" or the "Company") ... will present at the Acumen,BioFin Rodman & Renshaw 9th ... Eastern time. The conference will be held on November,5 ... The presentation will be simultaneously webcast and a ...
... Provides Revised Timing on Interim Celgosivir Viral Kinetics Study ... ... Oct. 31 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; OTC: MGIFF), a clinical-stage developer ... Renshaw 9th Annual,Healthcare Conference being held at the New York Palace Hotel ...
Cached Biology Technology:Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 3MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... Calif. Conservation biologist Michael Allen will give a ... 6 titled "In the Crosshairs: California,s Environment." The hour-long lecture ... Doors open at 6:15 p.m. Seating is open. In his ... Conservation Biology at UC Riverside, plans to discuss what the ...
... STILLWATER, Okla. , April 27 Southwest Bancorp, Inc. (Nasdaq: ... offering of 4,000,000 shares of common stock at a price to the public ... million .  The offering was increased from the previously announced offering size of ... April 29, 2010 . , , ...
... Recently the media has begun to criticize those ... financial reform legislation, or Consumer Financial Protection Agency (CFPA).  Although ... weeks, possibly due to the fact that our Senate is ... of the sweeping bill, we are still not seeing this ...
Cached Biology News:Public lecture at UC Riverside to highlight California's environment 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Pay1Day Asks, Who is Writing our Proposed Consumer Protection Bill? 2
... protein size markers are a mixture of ... to 100 kDa. The markers provide precise ... after staining with Coomassie blue. Because each ... sequence, the markers can also be detected ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... 220 V, is used for agitation and mixing ... staining and destaining of gels and blots, and ... (8-40 rpm) and can handle a maximum load ... two 29 x 21 cm platforms covered with ...
... (3-ethylbenzthiazoline-6-sulfonic Acid) Clear to very pale ... H 2 O 2 in a citrate ... that is soluble, safe, convenient and has good ... intense blue-green color that can be measured at ...
Biology Products: